RT Journal Article
SR Electronic
T1 Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.05.20241927
DO 10.1101/2020.12.05.20241927
A1 Kemp, SA
A1 Collier, DA
A1 Datir, R
A1 Gayed, S
A1 Jahun, A
A1 Hosmillo, M
A1 Ferreira, IATM
A1 Rees-Spear, C
A1 Mlcochova, P
A1 Lumb, Ines Ushiro
A1 Roberts, David
A1 Chandra, Anita
A1 Temperton, N
A1 The CITIID-NIHR BioResource COVID-19 Collaboration
A1 The COVID-19 Genomics UK (COG-UK) Consortium
A1 Sharrocks, K
A1 Blane, E
A1 Briggs, JAG
A1 van Gils, MJ
A1 Smith, KGC
A1 Bradley, JR
A1 Smith, C
A1 Goldstein, RA
A1 Goodfellow, IG
A1 Smielewska, A
A1 Skittrall, JP
A1 Gouliouris, T
A1 Gkrania-Klotsas, E
A1 Illingworth, CJR
A1 McCoy, LE
A1 Gupta, RK
YR 2020
UL http://medrxiv.org/content/early/2020/12/11/2020.12.05.20241927.abstract
AB SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics are designed around Wuhan-1 Spike, this raises the theoretical possibility of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. Here we report fatal SARS-CoV-2 escape from neutralising antibodies in an immune suppressed individual treated with convalescent plasma, generating whole genome ultradeep sequences by both short and long read technologies over 23 time points spanning 101 days. Little evolutionary change was observed in the viral population over the first 65 days despite two courses of remdesivir. However, following convalescent plasma we observed dynamic virus population shifts, with the emergence of a dominant viral strain bearing D796H in S2 and ΔH69/ΔV70 in the S1 NTD of the Spike protein. As serum neutralisation waned, viruses with the escape genotype diminished in frequency, before returning during a final, unsuccessful course of convalescent plasma. In vitro, the Spike escape variant conferred decreased sensitivity to multiple units of convalescent plasma/sera from different recovered patients, whilst maintaining infectivity similar to wild type. These data reveal strong positive selection on SARS-CoV-2 during convalescent plasma therapy and identify the combination of Spike mutations D796H and ΔH69/ΔV70 as a broad antibody resistance mechanism against commonly occurring antibody responses to SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRKG is supported by a Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA). LEM is supported by a Medical Research Council Career Development Award (MR/R008698/1). SAK is supported by the Bill and Melinda Gates Foundation via PANGEA grant: OPP1175094. DAC is supported by a Wellcome Trust Clinical PhD Research Fellowship. CJRI acknowledges MRC funding (ref: MC_UU_00002/11). This research was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and the Cambridge Clinical Trials Unit (CCTU) and by the UCL Coronavirus Response Fund and made possible through generous donations from UCLs supporters alumni and friends (LEM). JAGB is supported by the Medical Research Council (MC_UP_1201/16).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the East of England Cambridge Central Research Ethics Committee (17/EE/0025). The patient provided written informed consent. Additional controls with COVID19 were enrolled to the NIHR BioResource Centre Cambridge under ethics review board (17/EE/0025). Written consent to publish the report was obtained after death from the patients family.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, RKG, upon reasonable request.